SEHK:9606Biotechs
Duality Biotherapeutics (SEHK:9606) Stock Grapples With Revenue Collapse And Heavy Losses
Duality Biotherapeutics just reminded investors what high conviction in early stage oncology really looks like. The stock closed at HK$200.2 on the day of the H1 2026 release, with the market reacting to a story that is still all about scale of losses rather than clean profitability. The headline is simple. Revenue sat at ¥219.33 million for the half, while the company booked a net loss of ¥917.55 million and a basic loss per share of ¥10.2.
For a company often framed as a long term growth...